基于NGS的RNA定序市场（按应用、产品、最终用户和技术）－全球预测2025-2032

预计到 2032 年，基于 NGS 的 RNA定序市场将成长至 102 亿美元，复合年增长率为 18.21%。

主要市场统计数据
基准年2024年	26.7亿美元
预计2025年	31.7亿美元
预测年份：2032年	102亿美元
复合年增长率（%）	18.21%

全面介绍基于NGS的RNA定序创新及其对临床流程和转化研究生物资讯整合的影响

基于次世代定序仪(NGS) 的 RNA 定序已从学术研究发展成为支持发现、诊断和治疗开发的基础平台。这项技术能够以高灵敏度和分辨率定量转录组，现已支持从生物标记鑑定到研究细胞异质性的多种应用。随着实验室采用更复杂的工作流程和计算流程，RNA定序在从早期研究到临床应用的决策中的作用日益凸显。

此外，文库製备、读长优化和多模态整合的创新正在拓展RNA定序在复杂生物环境中的效用。这些技术进步伴随着实验室实践的转变、对可重复分析的期望不断提高以及对监管合规的新要求。因此，学术界、诊断学界和产业界的领导者不仅必须了解技术本身，还必须了解样本处理、资料管治和跨学科合作等营运方面的考量。

本介绍为需要将其科学能力与策略目标结合的相关人员提供了一个讨论框架，强调了为什么 RNA 定序现在已成为转化流程中的核心资产，并概述了以下章节中的观点。

重新定义跨学科 RNA 定序研究、临床转化和生物资讯学工作流程的变革性转变

RNA定序模式正在再形成，这不仅源自于原始通量的提升，也源自于多种因素的汇聚。首先，从批量转录组学到单细胞和空间转录组学的转变，透过揭示细胞异质性和组织结构，从根本上改变了生物学解读。这种转变需要新的样品製备方案、复杂的品管以及能够解析稀疏数据的分析方法。因此，研究团队现在在设计实验时会考虑细胞分辨率，这会影响从试剂选择到下游计算资源的各个方面。

其次，长读长定序技术作为补充方法应运而生，能够侦测短读长技术常常遗漏的全长异构体和复杂的转录本结构。这种能力加速了我们对可变剪接、融合转录物和转录本异构体调控的理解，并有助于标靶检验和生物标记优化。由于不同的错误概况和资料格式，采用长读长方法也需要重新评估文库建置工作流程和资料储存方法。

第三，与多体学和云端生物资讯学平台的整合正在推动跨实验室的协作和可重复分析。模组化和可互通的工作流程使团队能够将转录组数据与蛋白质组学和表观基因相结合，从而产生更稳健的生物学假设。这些转变不仅仅是技术上的；它们正在改变组织机构确定投资优先顺序、建立合作机制以及将研究发现转化为临床应用的方式。

2025年美国提案关税对RNA定序工作流程营运成本、供应链和策略采购的累积影响

影响关税的政策变化会波及生命科学供应链，影响成本、供应商关係和筹资策略。在试剂、设备和专用耗材跨境运输的情况下，关税上涨会增加货物的到岸成本，并促使企业重新评估筹资策略。对于许多实验室而言，这会导致采购週期延长，更加重视库存管理，采购团队也会优先考虑更长的前置作业时间和寻找替代供应商，以缓解供应中断的影响。

此外，由于研究机构和供应商力求降低跨境关税和货币波动的影响，关税可能会加速在地化和近岸外包的进程。供应商可以透过建立区域製造中心或优化产品系列来应对，以减少受关税影响的零件数量。同时，服务供应商和委外研发机构也可以透过提供端到端的交钥匙解决方案来简化研究机构和临床实验室的采购流程，从而为客户吸收部分供应链风险。

因此，研究团队在选择仪器和耗材时，必须审查供应商合约条款，考虑多方采购，并考虑整体拥有成本。此外，策略性采购决策将越来越强调在试剂和平台之间灵活切换，同时又不影响供应的连续性、区域支援和数据可比较性。最终，关税相关的压力正促使企业采用更具弹性的供应链策略，并更加重视平衡成本、可靠性和绩效的伙伴关係模式。

将应用产品最终用户和技术与差异化工作流程和价值创造路径连结起来的关键细分洞察

透过应用视角分析采用情况，可以揭示影响需求和投资的不同用例。生物标记发现着重于早期识别和检验，需要高通量可重复性和严格的检验流程，以支援下游临床应用。药物动力学研究强调定量准确性，标靶辨识需要广泛的转录组覆盖，毒性研究则优先考虑对稀有或低丰度转录物的敏感性。基因表现表现谱分析涵盖适用于群体层级讯号的批量方法，以及单细胞和空间分析，以揭示细胞和微环境的细微差别。个人化医疗需要整合伴随诊断和治疗监测，以提供可操作的、针对患者的见解和监管级证据。

在产品层面，酵素、试剂和试剂套件等耗材决定了检测的灵敏度和一致性，而文库製备平台、定序仪和资料分析平台等设备则决定了通量、读取品质和工作流程自动化。服务层面则透过生物资讯分析、计划管理和样品製备的专业知识进一步提升价值，减少实施阻力，加速洞察速度。产品和服务之间的这种区别影响筹资策略以及内部团队和外部合作伙伴之间的分工。

最终用户展现出不同的优先级，这会影响解决方案的设计和支援模型。由研究机构和大学组成的学术和政府研究机构优先考虑方法灵活性和新颖的应用；而包括医院和独立实验室在内的临床诊断实验室则强调法规遵循、样本可追溯性和周转时间。受託研究机构采用交付主导的模式，需要可扩展的工作流程和强大的品管；而製药和生物技术公司则在发现吞吐量与临床前和临床开发所需的严谨性之间取得平衡。

这种技术细分凸显了批量测序是群体和队列研究的支柱，长读长测序提供了无与伦比的异构体和结构洞察，单细胞测序解决了细胞异质性问题，而空间转录组学则能够捕捉组织背景。每种技术对实验设计、数据处理和解读都有不同的要求，成功的专案将根据特定的科学挑战量身定制投资，同时确保在采用多种技术策略时实现互通性。

决定招募模式的区域动态和能力概况；世界主要地区的监管考量和伙伴关係机会；

地区差异导致了不同的应用模式和策略重点。在美洲，密集的研究机构和生技公司网络支撑着一个充满活力的技术应用、转化合作和公私合营关係生态系统。这种环境促进了新型定序方法的快速部署，并促进了设备供应商和早期采用者之间的密切合作，而法律规范和报销途径则持续影响临床应用的时间表。

欧洲、中东和非洲呈现出多元化的格局，协调一致的监管环境、跨境研究联盟和国家资金筹措计画正在塑造能力建设。该地区许多国家正在对基础设施进行战略投资，以支持基因组医学和转化研究，为联盟主导的研究以及区域製造和经销伙伴创造了机会。同时，不同的管理体制鼓励强调互通性、资料保护和跨司法管辖区合规的解决方案。

在亚太地区，对创新工作流程的规模化、在地化和快速应用的关注，正在推动学术中心和商业生物技术公司进行大量投资。该地区的优先事项通常包括建立国内生产能力、扩展临床测序服务以及整合数位健康平台。因此，在这些地区运营的公司和机构必须根据采购惯例、监管期望以及支持大规模部署的区域伙伴关係关係的差异，量身定制其合作策略。

公司层面的竞争定位、伙伴关係和能力差异化策略考量，塑造 RNA 定序生态系统

RNA定序生态系统中的领先公司透过整合专有化学技术、仪器工程、软体生态系统和降低进入门槛的服务，脱颖而出。将强大的硬体与可扩展的云端分析技术以及强大的客户支援相结合的公司，能够为高通量研究和临床客户创造可持续的优势。此外，提供整合耗材和检验的工作流程的供应商可以减少差异性并加快获得结果的速度。

设备供应商、试剂製造商和生物资讯公司之间的合作正在创造更多端到端解决方案，这对寻求承包服务的机构极具吸引力。与受託研究机构和学术联盟的策略联盟正在进一步拓展空间转录组学和单细胞分析等专业应用的覆盖范围。同时，以服务为导向的公司提供深厚的生物资讯专业知识和样本处理能力，正在帮助缺乏内部计算资源的研究机构填补这一空白。

随着竞争动态的演变，投资于互通性、开放 API 和社群主导的分析框架的公司更有能力获得研究网路的长期参与。同样重要的是，能够透过同行评审的检验和符合法规的研究来检验其在现实世界中的效用。这些公司层面的策略将在塑造整个生态系统的采用、合作伙伴选择和客户维繫发挥核心作用。

为行业领导者提供实用的优先建议，以加速采用，降低风险并从 RNA 测序投资中获取价值

领导者首先应将技术选择与研究目标结合，并确保所选定序方法（批量定序、单细胞定序、长读长定序或空间定序）能够直接解决其关键的生物学问题。这种协调可以减少下游返工并优化资源配置。其次，组织机构应投资标准化样本工作流程和品管查核点，以确保在不同机构和研究中获得可重复的结果，从而增强对研究发现和临床结果的信心。

为了降低供应链和采购风险，研究机构应与多家供应商建立合作关係，并探索能够在贸易政策变化时提供连续性的区域采购方案。同时，建构内部生物资讯能力，并利用外部服务合作伙伴进行专业分析，可以创建一个平衡控制力和扩充性的混合模式。投资可互通的资料基础设施和清晰的资料管治政策，可以促进多组体学整合、协作以及对当地法规和政策的遵守。

最后，产业领导者应在开发生命週期的早期阶段优先进行透明的检验研究和监管参与。透过严格的外部检验研究证明临床效用和稳健性，将加速相关人员的认可，并支持下游应用。遵循这些优先行动，将使企业能够从RNA测序技术中获得更大的价值，同时降低营运和策略风险。

透明的调查方法，解释如何分析资料来源以及为综合研究结果和确保可重复性而采取的检验步骤

该分析整合了主要专家访谈、已发表通讯协定的技术评估以及同行评审文献的系统综述的结果，以三角测量趋势和实际意义。主要的定性输入来自实验室主任、采购主管和生物资讯专家，旨在了解操作实践和检验重点。技术评估包括对工作流程要素（例如文库製备方法、读长影响和样本品质阈值）进行基准测试，以明确技术是否适合用途。

分析方法强调可重复性和可追溯性。关键声明已通过多个独立资讯来源检验，并阐明了方法学的局限性。比较评估着重于差异化能力而非定量市场指标，并使用案例研究来说明技术选择如何影响药物研发和临床工作流程的结果。在适当的情况下，从监管文件和公开指南中获取了有关临床实施和合规性的见解。

该调查方法旨在为读者提供所提出的研究结果和建议的明确理由，透过强调影响 RNA 定序技术部署和采用的技术细节和实际限制来支持明智的决策。

将技术进步的营运现实与策略行动连结并指导相关人员进行实用化。

最后，RNA定序正处于技术创新与营运转型的交会点。单细胞、长读长和空间转录组学的进步拓展了可解决的生物学问题的范围，而不断变化的供应链动态和监管环境也要求新的采购和专案管理方法。那些根据科学目标做出深思熟虑的技术选择、投资可重复的工作流程并建立灵活伙伴关係的组织，将最有可能最大限度地发挥这些进步的价值。

展望未来，最成功的计画将整合强大的生物资讯学，优先考虑跨学科合作，并为影响临床应用的监管和商业性限製做好准备。透过采用弹性供应策略并投资检验途径，相关人员可以加速将转录组学见解转化为可操作的临床和研究成果。这一结论强调了製定策略规划的必要性，该规划应兼顾创新、实用性和合规性，以实现永续的影响。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 利用整合的单细胞和空间转录组学进行肿瘤微环境分析
• 扩展直接RNA定序技术以准确检测RNA修饰
• 结合人工智慧和机器学习进行转录组数据解释
• 用于分析全长转录异构体的长读定序平台的实现
• 引入云原生流程来加速大规模 RNA-seq 资料分析
• 基于NGS的肿瘤RNA诊断标准化临床试验的开发
• 整合RNA定序与蛋白质体学和代谢体学的多体学方法
• 监管协调努力简化基于RNA的伴随诊断的核准
• 样品製备工作流程高通量自动化的成本最佳化策略
• 可携式定序设备的出现，使照护现场转录组分析成为可能

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 基于NGS的RNA定序市场（依应用）

• 生物标记发现
  • 早期生物标记识别
  • 检验
• 药物研发
  • 药物动力学研究
  • 目标识别
  • 毒理学研究
• 基因表现
  • 批量分析
  • 单细胞分析
  • 空间剖析
• 个人化医疗
  • 伴随诊断
  • 治疗监测

9. 以NGS为基础的RNA定序市场（依产品）

• 耗材
  • 酵素
  • 试剂和套件
• 装置
  • 数据分析平台
  • 文库製备设备
  • 序列器
• 服务
  • 生物资讯分析服务
  • 计划管理服务
  • 样品製备服务

第 10 章基于 NGS 的 RNA定序市场（按最终用户划分）

• 学术和政府
  • 研究机构
  • 大学
• 临床诊断实验室
  • 医院检查室
  • 独立研究机构
• 合约研究组织
• 製药和生物技术公司
  • 生技公司
  • 製药公司

11. 基于NGS的RNA定序市场（依技术）

• 批量序列
• 长读定序
• 单细胞定序
• 空间转录组学

12. 基于NGS的RNA定序市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

13. 基于NGS的RNA定序市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 基于NGS的RNA定序市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies Ltd.
  • BGI Genomics Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Eurofins Scientific SE
  • PerkinElmer, Inc.

The NGS-Based RNA-Sequencing Market is projected to grow by USD 10.20 billion at a CAGR of 18.21% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.67 billion
Estimated Year [2025]	USD 3.17 billion
Forecast Year [2032]	USD 10.20 billion
CAGR (%)	18.21%

Comprehensive introduction to NGS-based RNA sequencing innovations and their implications for translational research clinical pipelines and bioinformatics integration

Next-generation sequencing (NGS)-based RNA sequencing has progressed from an academic curiosity to a foundational platform that underpins discovery, diagnostics, and therapeutic development. The technique's capacity to quantify transcriptomes with high sensitivity and resolution now supports diverse applications ranging from biomarker identification to the interrogation of cellular heterogeneity. As laboratories adopt more sophisticated workflows and computational pipelines, RNA sequencing increasingly informs decisions across early-stage research and clinical translation.

In addition, innovations in library preparation, read-length optimization, and multi-modal integration have expanded the utility of RNA sequencing in complex biological contexts. These technical advances have been accompanied by shifts in laboratory practices, heightened expectations for reproducible analyses, and new demands for regulatory alignment. Consequently, leaders in academia, diagnostics, and industry must understand not only the technology, but also operational considerations such as sample handling, data governance, and cross-disciplinary collaboration.

This introduction frames the discussion for stakeholders who need to align scientific capabilities with strategic objectives. It highlights why RNA sequencing is now a central asset in translational pipelines, and it outlines the contours of the landscape that follow in subsequent sections.

Transformative shifts redefining RNA sequencing research, clinical translation, and bioinformatics workflows across disciplines

The landscape of RNA sequencing has been reshaped by several convergent forces that extend beyond raw throughput improvements. First, the move from bulk to single-cell and spatial transcriptomics has fundamentally changed biological interpretation by illuminating cellular heterogeneity and tissue architecture. This transition has demanded new sample preparation protocols, refined quality controls, and analytical methods capable of resolving sparse data. As a result, research teams now design experiments with cellular resolution in mind, which influences everything from reagent selection to downstream computational resources.

Second, long-read sequencing technologies have emerged as a complementary approach, enabling the detection of full-length isoforms and complex transcript structures that short reads can miss. This capability is accelerating our understanding of alternative splicing, fusion transcripts, and transcript isoform regulation, which in turn informs target validation and biomarker refinement. The adoption of long-read approaches also requires reassessment of library construction workflows and data storage approaches because of differing error profiles and data formats.

Third, integration with multi-omics and cloud-enabled bioinformatics platforms is driving collaborative, reproducible analyses across institutions. As workflows become modular and interoperable, teams can combine transcriptomic data with proteomics and epigenomics to generate higher-confidence biological hypotheses. Taken together, these shifts are not merely technical; they alter how organizations prioritize investments, structure collaborations, and translate discovery into clinical application.

Cumulative effects of proposed United States tariffs in 2025 on operational costs supply chains and strategic sourcing for RNA sequencing workflows

Policy changes that affect tariffs can ripple through the life sciences supply chain, influencing costs, supplier relationships, and procurement strategies. In contexts where reagents, instruments, and specialized consumables cross borders, higher duties increase the landed cost of goods and create incentives to revisit sourcing strategies. For many laboratories, this results in longer procurement cycles and elevated attention to inventory management, with procurement teams prioritizing longer lead times and alternative suppliers to mitigate supply interruptions.

Moreover, tariffs can accelerate localization and near-shoring efforts as institutions and vendors seek to reduce exposure to cross-border duties and currency volatility. Suppliers may respond by establishing regional manufacturing hubs or by optimizing their product portfolios to reduce the number of tariff-affected components. In parallel, service providers and contract research organizations may adapt by offering bundled, end-to-end solutions that absorb some supply chain risks on behalf of customers, thereby simplifying procurement for research and clinical laboratories.

Consequently, research groups must reassess vendor contractual terms, explore multi-sourcing, and consider the total cost of ownership when selecting instruments and consumables. In addition, strategic purchasing decisions will increasingly weigh supply continuity, regional support, and the flexibility to pivot between reagents or platforms without compromising data comparability. Ultimately, tariff-related pressures are prompting organizations to adopt more resilient supply chain strategies and a greater emphasis on partnership models that balance cost, reliability, and performance.

Key segmentation insights linking applications products end users and technologies to differentiated workflows and value creation pathways

Analyzing adoption through the lens of application reveals distinct use-cases that shape requirements and investments. Biomarker discovery, with its focus on early-stage identification and validation, demands high-throughput reproducibility and rigorous validation pipelines to support downstream clinical translation. Drug discovery and development imposes orthogonal constraints: pharmacokinetic studies emphasize quantitative precision, target identification requires broad transcriptome coverage, and toxicology studies prioritize sensitivity for rare or low-abundance transcripts. Gene expression profiling spans bulk approaches suited to population-level signals as well as single-cell and spatial profiling that reveal cellular and microenvironmental nuances. Personalized medicine requires integration across companion diagnostics and therapeutic monitoring to deliver actionable, patient-specific insights and regulatory-grade evidence.

From a product perspective, consumables such as enzymes, reagents and kits determine assay sensitivity and consistency, while instruments including library preparation platforms, sequencers and data analysis platforms define throughput, read quality, and workflow automation. Services layer adds further value through bioinformatics analysis, project management, and sample preparation expertise that reduce adoption friction and accelerate time-to-insight. These product and service distinctions influence procurement strategies and the division of labor across internal teams and external partners.

End users exhibit varied priorities that influence solution design and support models. Academic and government research entities-comprising research institutes and universities-prioritize methodological flexibility and novel applications, whereas clinical diagnostics laboratories including hospital and independent labs emphasize regulatory compliance, sample traceability, and turnaround times. Contract research organizations operate on delivery-driven models that require scalable workflows and robust quality management, and pharmaceutical and biotechnology companies balance discovery throughput with the rigor needed for preclinical and clinical development.

Technology segmentation underscores that bulk sequencing remains a workhorse for population and cohort studies, long-read sequencing provides unmatched isoform and structural insights, single-cell sequencing resolves cellular heterogeneity, and spatial transcriptomics captures tissue context. Each technology imposes different requirements for experimental design, data processing, and interpretation, and successful programs calibrate their investments to match the specific scientific question while ensuring interoperability where multi-technology strategies are employed.

Regional dynamics and capability profiles that determine adoption patterns regulatory considerations and partnership opportunities across major global regions

Regional differences drive distinct adoption patterns and strategic priorities. In the Americas, research-intensive institutions and a dense network of biotechnology companies support a vibrant ecosystem for technology adoption, translational collaborations, and private-public partnerships. This environment encourages rapid deployment of new sequencing modalities and close engagement between instrument vendors and early adopters, while regulatory frameworks and reimbursement pathways continue to influence clinical translation timelines.

Europe, the Middle East and Africa present a heterogeneous landscape in which regulatory harmonization efforts, cross-border research consortia, and national funding initiatives shape capacity building. Many countries in this region invest strategically in infrastructure to support genomic medicine and translational research, creating opportunities for consortium-driven studies and regional manufacturing or distribution partnerships. Meanwhile, disparate regulatory regimes encourage solutions that emphasize interoperability, data protection, and cross-jurisdictional compliance.

Asia-Pacific demonstrates a strong emphasis on scale, localization, and rapid uptake of innovative workflows, with significant investments in both academic centers and commercial biotech. Regional priorities often include building domestic manufacturing capability, expanding clinical sequencing services, and integrating digital health platforms. Consequently, companies and institutions operating across these regions must tailor their engagement strategies to account for differences in procurement practices, regulatory expectations, and local partnerships that support deployment at scale.

Strategic company-level insights into competitive positioning partnerships and capability differentiation shaping the RNA sequencing ecosystem

Leading organizations in the RNA sequencing ecosystem differentiate through a combination of proprietary chemistry, instrument engineering, software ecosystems, and services that lower barriers to adoption. Companies that pair robust hardware with scalable cloud-enabled analysis and strong customer support create durable advantages for high-throughput research and clinical customers. In addition, vendors that offer integrated consumables and validated workflows reduce variability and accelerate time-to-results, which is particularly valuable for clinical diagnostics and regulated studies.

Partnerships between instrument providers, reagent manufacturers, and bioinformatics firms have produced more end-to-end solutions that appeal to organizations seeking turnkey capabilities. Strategic alliances with contract research organizations and academic consortia further extend reach into specialized applications such as spatial transcriptomics and single-cell analytics. Meanwhile, service-focused firms that provide deep bioinformatics expertise and sample handling capabilities help bridge gaps for institutions that lack in-house computational resources.

As competitive dynamics evolve, companies that invest in interoperability, open APIs, and community-driven analysis frameworks are better positioned to capture long-term engagement from research networks. Equally important is the ability to demonstrate real-world utility through peer-reviewed validations and regulatory-compliant studies that verify performance in clinically relevant settings. These company-level strategies are central to shaping adoption, partner selection, and customer retention across the ecosystem.

Practical and prioritized recommendations for industry leaders to accelerate adoption reduce risk and capture value from RNA sequencing investments

Leaders should begin by aligning research objectives with technology selection, ensuring that the chosen sequencing approach-bulk, single-cell, long-read, or spatial-directly addresses the primary biological question. This alignment reduces downstream rework and optimizes resource allocation. Next, organizations should invest in standardized sample workflows and quality-control checkpoints that enable reproducible outcomes across sites and studies, thereby enhancing confidence in both discovery and clinical results.

To mitigate supply chain and procurement risks, institutions should cultivate multi-vendor relationships and explore regional sourcing options that can provide continuity under shifting trade policies. Concurrently, building internal bioinformatics capacity while leveraging external service partners for specialized analyses creates a hybrid model that balances control with scalability. Investing in interoperable data infrastructures and clear data governance policies will facilitate multi-omics integration, collaboration, and compliance with regional regulations.

Finally, industry leaders should prioritize transparent validation studies and regulatory engagement early in the development lifecycle. Demonstrating clinical utility and robustness through rigorous, externally validated studies accelerates stakeholder buy-in and supports downstream adoption. By following these prioritized actions, organizations can extract greater value from RNA sequencing technologies while reducing operational and strategic risk.

Transparent research methodology describing data sources analytical approaches and validation steps used to synthesize findings and ensure reproducibility

The analysis synthesizes insights from primary interviews with domain experts, technical evaluation of published protocols, and systemic review of peer-reviewed literature to triangulate trends and practical implications. Primary qualitative inputs were obtained from laboratory directors, procurement leads, and bioinformatics specialists to capture operational realities and validation priorities. Technical assessments included benchmarking of workflow elements such as library preparation methods, read-length implications, and sample quality thresholds to contextualize technology fit for purpose.

Analytical methods emphasize reproducibility and traceability: key assertions were validated against multiple independent sources and methodological limitations were explicitly noted. Comparative assessments focused on capability differentiation rather than quantitative market metrics, and case studies were used to illustrate how technology choices influenced outcomes across discovery and clinical workflows. Where appropriate, regulatory documents and publicly available guidance informed considerations around clinical implementation and compliance.

This methodology aims to provide readers with a transparent basis for the findings and recommendations presented, and it supports informed decision-making by highlighting both technical nuances and practical constraints that affect deployment and adoption of RNA sequencing technologies.

Concluding synthesis connecting technological advances operational realities and strategic actions to guide stakeholders toward practical implementation

In closing, RNA sequencing stands at the confluence of technological innovation and operational transformation. Advances in single-cell, long-read, and spatial transcriptomics are expanding the scope of biological questions that can be addressed, while evolving supply chain dynamics and regulatory landscapes require new approaches to procurement and program management. Organizations that thoughtfully align technology choices with scientific objectives, invest in reproducible workflows, and build flexible partnerships will be best positioned to capture the value of these advances.

Moving forward, the most successful programs will integrate robust bioinformatics, prioritize cross-disciplinary collaboration, and prepare for regulatory and commercial constraints that influence clinical translation. By adopting resilient supply strategies and investing in validation pathways, stakeholders can accelerate the translation of transcriptomic insights into actionable clinical and research outcomes. This conclusion underscores the need for strategic planning that bridges innovation, practicality, and compliance to enable sustainable impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of single-cell and spatial transcriptomics integration for tumor microenvironment profiling
• 5.2. Expansion of direct RNA sequencing technologies for accurate detection of RNA modifications
• 5.3. Incorporation of artificial intelligence and machine learning for transcriptomic data interpretation
• 5.4. Implementation of long-read sequencing platforms to resolve full-length transcript isoforms
• 5.5. Deployment of cloud-native pipelines to accelerate large-scale RNA-seq data analysis
• 5.6. Development of standardized clinical assays for NGS-based RNA diagnostics in oncology
• 5.7. Integration of multiomics approaches combining RNA-seq with proteomics and metabolomics
• 5.8. Regulatory harmonization efforts to streamline approval of RNA-based companion diagnostics
• 5.9. Cost optimization strategies through high-throughput automation of sample preparation workflows
• 5.10. Emergence of portable sequencing devices enabling point-of-care transcriptome analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NGS-Based RNA-Sequencing Market, by Application

• 8.1. Biomarker Discovery
  • 8.1.1. Early-Stage Biomarker Identification
  • 8.1.2. Validation
• 8.2. Drug Discovery & Development
  • 8.2.1. Pharmacokinetic Studies
  • 8.2.2. Target Identification
  • 8.2.3. Toxicology Studies
• 8.3. Gene Expression Profiling
  • 8.3.1. Bulk Profiling
  • 8.3.2. Single-Cell Profiling
  • 8.3.3. Spatial Profiling
• 8.4. Personalized Medicine
  • 8.4.1. Companion Diagnostics
  • 8.4.2. Therapeutic Monitoring

9. NGS-Based RNA-Sequencing Market, by Product

• 9.1. Consumables
  • 9.1.1. Enzymes
  • 9.1.2. Reagents And Kits
• 9.2. Instruments
  • 9.2.1. Data Analysis Platforms
  • 9.2.2. Library Prep Instruments
  • 9.2.3. Sequencers
• 9.3. Services
  • 9.3.1. Bioinformatics Analysis Services
  • 9.3.2. Project Management Services
  • 9.3.3. Sample Preparation Services

10. NGS-Based RNA-Sequencing Market, by End User

• 10.1. Academic & Government
  • 10.1.1. Research Institutes
  • 10.1.2. Universities
• 10.2. Clinical Diagnostics Laboratories
  • 10.2.1. Hospital Laboratories
  • 10.2.2. Independent Laboratories
• 10.3. Contract Research Organizations
• 10.4. Pharmaceutical & Biotechnology Companies
  • 10.4.1. Biotechnology Companies
  • 10.4.2. Pharmaceutical Companies

11. NGS-Based RNA-Sequencing Market, by Technology

• 11.1. Bulk Sequencing
• 11.2. Long-Read Sequencing
• 11.3. Single-Cell Sequencing
• 11.4. Spatial Transcriptomics

12. NGS-Based RNA-Sequencing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. NGS-Based RNA-Sequencing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. NGS-Based RNA-Sequencing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Illumina, Inc.
  • 15.3.2. Thermo Fisher Scientific Inc.
  • 15.3.3. QIAGEN N.V.
  • 15.3.4. Pacific Biosciences of California, Inc.
  • 15.3.5. Oxford Nanopore Technologies Ltd.
  • 15.3.6. BGI Genomics Co., Ltd.
  • 15.3.7. F. Hoffmann-La Roche Ltd
  • 15.3.8. Agilent Technologies, Inc.
  • 15.3.9. Eurofins Scientific SE
  • 15.3.10. PerkinElmer, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NGS-BASED RNA-SEQUENCING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 270. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 271. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 272. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 273. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
• TABLE 274. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
• TABLE 275. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
• TABLE 276. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
• TABLE 277. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2024 (USD MILLION)
• TABLE 278. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2025-2032 (USD MILLION)
• TABLE 279. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
• TABLE 280. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
• TABLE 281. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 282. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 283. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 284. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 285. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 286. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 287. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 288. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 289. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLI